Vnitr Lek 2018, 64(6):635-641 | DOI: 10.36290/vnl.2018.087

Familial adenomatous polyposis: complex patient management

Jiří Cyrany1,2,*, Jan Bureš1, Stanislav Rejchrt1, Marcela Kopáčová1
1 II. interní gastroenterologická klinika LF UK a FN Hradec Králové
2 Interní oddělení Oblastní nemocnice Jičín a.s.

Familial adenomatous polyposis (FAP) is a hereditary disease characterized by presence of numerous colorectal adenomas. It often exposes its carrier to absolute risk of colorectal cancer, but also to other extracolonic tumours (especially to duodenal cancer and desmoid). Screening and surveillance of FAP patients leads to reduction of colorectal cancer incidence and mortality. Colonoscopy/lower endoscopy and esophagogastroduodenoscopy (including use of side-viewing endoscope) are the principal examinations. Colectomy is the standard therapeutic procedure, but endoscopic therapy plays relevant role both in upper and lower gastrointestinal tract. Recent international guidelines and some new tools for severity classification enable effectively reduce the mortality related to this disease by individualized patient management.

Keywords: colorectal cancer; familial adenomatous polyposis

Received: November 1, 2017; Accepted: April 18, 2018; Published: June 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cyrany J, Bureš J, Rejchrt S, Kopáčová M. Familial adenomatous polyposis: complex patient management. Vnitr Lek. 2018;64(6):635-641. doi: 10.36290/vnl.2018.087.
Download citation

References

  1. Vasen HF, Moslein G, Alonso A et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57(5): 704-713. Dostupné z DOI: <http://dx.doi.org/10.1136/gut.2007.136127>. Go to original source... Go to PubMed...
  2. Balmana J, Balaguer F, Cervantes A et al. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2013; 24(Suppl 6): vi73-vi80. Dostupné z DOI: <http://dx.doi.org/10.1093/annonc/mdt209>. Go to original source... Go to PubMed...
  3. Stoffel EM, Mangu PB, Gruber SB et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 2015; 33(2): 209-217. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2014.58.1322>. Go to original source... Go to PubMed...
  4. [National Comprehensive Cancer Network]. Genetic/Familial High-Risk Assessment: Colorectal. NCCN Clinical Practice Guidelines in Oncology 2017 [updated 10.10.2017; cited 20.10.2017]. Dostupné z WWW: <https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf>.
  5. Syngal S, Brand RE, Church JM et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol 2015; 110: 223-262; quiz 263. Dostupné z DOI: <http://dx.doi.org/10.1038/ajg.2014.435>. Go to original source... Go to PubMed...
  6. Herzig D, Hardiman K, Weiser M et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Inherited Polyposis Syndromes. Dis Colon Rectum 2017; 60(9): 881-894. Dostupné z DOI: <http://dx.doi.org/10.1097/DCR.0000000000000912>. Go to original source... Go to PubMed...
  7. Lynch PM, Morris JS, Wen S et al. A proposed staging system and stage-specific interventions for familial adenomatous polyposis. Gastrointest Endosc 2016; 84(1): 115-125. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gie.2015.12.029>. Go to original source... Go to PubMed...
  8. Spigelman AD, Williams CB, Talbot IC et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2(8666): 783-785. Go to original source... Go to PubMed...
  9. Saurin JC, Gutknecht C, Napoleon B et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22(3): 493-498. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2004.06.028>. Go to original source... Go to PubMed...
  10. Sourrouille I, Lefevre JH, Shields C et al. Surveillance of Duodenal Polyposis in Familial Adenomatous Polyposis: Should the Spigelman Score Be Modified? Dis Colon Rectum 2017; 60(11): 1137-1146. Dostupné z DOI: <http://dx.doi.org/10.1097/DCR.0000000000000903>. Go to original source... Go to PubMed...
  11. Hegde M, Ferber M, Mao R et al. [Working Group of the American College of Medical Genetics and Genomics (ACMG) Laboratory Quality Assurance Committee]. ACMG technical standards and guidelines for genetic testing for inherited colorectal cancer (Lynch syndrome, familial adenomatous polyposis, and MYH-associated polyposis). Genet Med 2014; 16(1): 101-116. Dostupné z DOI: <http://dx.doi.org/10.1038/gim.2013.166>. Go to original source... Go to PubMed...
  12. Grover S, Kastrinos F, Steyerberg EW et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA 2012; 308(5): 485-492. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2012.8780>. Go to original source... Go to PubMed...
  13. Repak R, Kohoutova D, Podhola M et al. The first European family with gastric adenocarcinoma and proximal polyposis of the stomach: case report and review of the literature. Gastrointest Endosc 2016; 84(4): 718-725. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gie.2016.06.023>. Go to original source... Go to PubMed...
  14. Kallenberg FG, Bastiaansen BA, Dekker E. Cap-assisted forward-viewing endoscopy to visualize the ampulla of Vater and the duodenum in patients with familial adenomatous polyposis. Endoscopy 2017; 49(2): 181-185. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0042-118311>. Go to original source... Go to PubMed...
  15. Alderlieste YA, Rauws EA, Mathus-Vliegen EM et al. Prospective enteroscopic evaluation of jejunal polyposis in patients with familial adenomatous polyposis and advanced duodenal polyposis. Fam Cancer 2013; 12(1): 51-56. Dostupné z DOI: <http://dx.doi.org/10.1007/s10689-012-9571-1>. Go to original source... Go to PubMed...
  16. Pennazio M, Spada C, Eliakim R et al. Small-bowel capsule endoscopy and device-assisted enteroscopy for diagnosis and treatment of small-bowel disorders: European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2015; 47(4): 352-376. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0034-1391855>. Go to original source... Go to PubMed...
  17. De Marchis ML, Tonelli F, Quaresmini D et al. Desmoid Tumors in Familial Adenomatous Polyposis. Anticancer Res 2017; 37(7): 3357-3366. Dostupné z DOI: <http://dx.doi.org/10.21873/anticanres.11702>. Go to original source... Go to PubMed...
  18. Steinhagen E, Hui VW, Levy RA et al. Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients. Am J Surg 2014; 208(5): 764-769. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjsurg.2014.03.012>. Go to original source... Go to PubMed...
  19. Gluck N, Strul H, Rozner G et al. Endoscopy and EUS are key for effective surveillance and management of duodenal adenomas in familial adenomatous polyposis. Gastrointest Endosc 2015; 81(4): 960-966. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gie.2014.08.029>. Go to original source... Go to PubMed...
  20. Basford PJ, Bhandari P. Endoscopic management of nonampullary duodenal polyps. Therap Adv Gastroenterol 2012; 5(2): 127-138. Dostupné z DOI: <http://dx.doi.org/10.1177/1756283X11429590>. Go to original source... Go to PubMed...
  21. Hyun JJ, Lee TH, Park JS et al. A prospective multicenter study of submucosal injection to improve endoscopic snare papillectomy for ampullary adenoma. Gastrointest Endosc 2017; 85(4): 746-755. Dostupné z DOI: <http://dx.doi.org/10.1016/j.gie.2016.08.013>. Go to original source... Go to PubMed...
  22. Watanabe Y, Ishida H, Baba H et al. Pancreas-sparing total duodenectomy for Spigelman stage IV duodenal polyposis associated with familial adenomatous polyposis: experience of 10 cases at a single institution. Fam Cancer 2017; 16(1): 91-98. Dostupné z DOI: <http://dx.doi.org/10.1007/s10689-016-9932-2>. Go to original source... Go to PubMed...
  23. Burke CA, Phillips R, Berger MF et al. Children's International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis. Clin Exp Gastroenterol 2017; 10: 177-185. Dostupné z DOI: <http://dx.doi.org/10.2147/CEG.S121841>. Go to original source... Go to PubMed...
  24. Lynch PM. Chemoprevention of familial adenomatous polyposis. Fam Cancer 2016; 15(3): 467-475. Dostupné z DOI: <http://dx.doi.org/10.1007/s10689-016-9901-9>. Go to original source... Go to PubMed...
  25. Pfizer s.r.o. Informační dopis ONSENAL 2011 [updated 4.4.2011; cited 20.10.2017]. Dostupné z WWW: <http://www.sukl.cz/uploads/Farmakovigilance/DHPC_for_Onsenal_EU_22March_CS.pdf>.
  26. Pfizer Inc. Withdrawal of Approval of Familial Adenomatous Polyposis Indication for Celebrex. [updated 8.6.2012; cited 20.10.2017]. Dostupné z WWW: <https://www.federalregister.gov/documents/2012/06/08/2012-13900/pfizer-inc-withdrawal-of-approval-of-familial-adenomatous-polyposis-indication-for-celebrex>.
  27. Státní ústav pro kontrolu léčiv. Formulář oznámení o použití neregistrovaného léčivého přípravku 2013 [updated 2.4.2013; cited 20.10.2017]. Dostupné z WWW: <http://www.sukl.cz/modules/unregistered/?rewrite=modules/unregistered>.
  28. West NJ, Clark SK, Phillips RK et al. Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. Gut 2010; 59(7): 918-925. Dostupné z DOI: <http://dx.doi.org//10.1136/gut.2009.200642>. Go to original source... Go to PubMed...
  29. Barrow P, Khan M, Lalloo F et al. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg 2013; 100(13): 1719-1731. Dostupné z DOI: <http://dx.doi.org/10.1002/bjs.9316>. Go to original source... Go to PubMed...
  30. Cyrany J. Familial Adenomatous Polyposis Registry in Czech Republic - History, Present and Future. Acta Medica (Hradec Kralove) 2017; 60(1): 55-57. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.